ADiTx Therapeutics Retained Earnings 2011-2026 | ADTX

Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.

Possible uses include

reinvestment in development (R&D, equipment, marketing)
debt repayment
acquisition of other companies
creation of reserves for the future

A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.

The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.

Annual Retained Earnings ADiTx Therapeutics

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-168 M	-128 M	-95 M	-67.4 M	-20.9 M	-11.7 M	-5.9 M	-213 K	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-213 K	-168 M	-62.1 M

Quarterly Retained Earnings ADiTx Therapeutics

2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-181 M	-174 M	-168 M	-163 M	-150 M	-142 M	-128 M	-117 M	-107 M	-101 M	-95 M	-86.8 M	-79.3 M	-73.4 M	-67.4 M	-43.3 M	-33.4 M	-27.3 M	-20.9 M	-20.9 M	-20.9 M	-20.9 M	-11.7 M	-11.7 M	-11.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-11.7 M	-181 M	-82.2 M

Retained Earnings of other stocks in the Biotechnology industry

Issuer	Retained Earnings	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-158 M	-	2.43 %	$ 254 M	Germany
Acer Therapeutics ACER	-141 M	-	2.71 %	$ 14 M	USA
Acorda Therapeutics ACOR	-1.19 B	-	-24.86 %	$ 820 K	USA
ADMA Biologics ADMA	-162 M	$ 15.87	-4.08 %	$ 3.78 B	USA
AgeX Therapeutics AGE	-131 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	-1.13 B	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	-308 M	-	-	$ 26.5 M	USA
AbCellera Biologics ABCL	-29.5 M	$ 3.54	-2.62 %	$ 1.06 B	Canada
I-Mab IMAB	-8.33 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	5.24 B	-	-	$ 40.3 B	USA
Biophytis SA BPTS	-17.1 M	-	-13.47 %	$ 169 M	France
Aptorum Group Limited APM	-72.4 M	$ 0.82	-0.73 %	$ 4.47 M	China
EyeGate Pharmaceuticals, Inc. EYEG	-108 M	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	-122 M	-	-18.52 %	$ 27.3 M	Britain
Akero Therapeutics AKRO	-826 M	-	-	$ 3.67 B	USA
Akouos AKUS	-168 M	-	0.23 %	$ 488 M	USA
Alpine Immune Sciences ALPN	-224 M	-	-	$ 2.17 B	USA
AlloVir ALVR	-715 M	-	4.14 %	$ 49.1 M	USA
Apellis Pharmaceuticals APLS	-3.01 B	$ 20.36	2.49 %	$ 2.57 B	USA
Ampio Pharmaceuticals AMPE	-243 M	-	-11.43 %	$ 502 K	USA
ANI Pharmaceuticals ANIP	-100 M	$ 75.13	-1.83 %	$ 1.45 B	USA
Applied Therapeutics APLT	-469 M	-	-	$ 8.42 M	USA
Autolus Therapeutics plc AUTL	-1.1 B	$ 1.51	-7.36 %	$ 385 M	Britain
Aravive ARAV	-616 M	-	-13.39 %	$ 1.45 M	USA
Adverum Biotechnologies ADVM	-1.07 B	-	-	$ 86.2 M	USA
Институт стволовых клеток человека ISKJ	69.4 M	-	-	-	Russia
Athersys ATHX	-583 M	-	3.77 %	$ 22.4 M	USA
ARCA biopharma ABIO	-83.7 M	-	1052.0 %	$ 415 M	USA
AVEO Pharmaceuticals AVEO	-675 M	-	-	$ 521 M	USA
Axsome Therapeutics AXSM	-1.31 B	$ 162.19	-1.15 %	$ 8.07 B	USA
BridgeBio Pharma BBIO	-3.82 B	$ 64.72	-2.73 %	$ 12.4 B	USA
Brainstorm Cell Therapeutics BCLI	-227 M	-	-2.5 %	$ 5.88 M	USA
BioDelivery Sciences International BDSI	-256 M	-	-4.8 %	$ 255 M	USA
Acasti Pharma ACST	-221 M	-	4.01 %	$ 150 M	Canada
BeiGene, Ltd. BGNE	-8.32 B	-	0.49 %	$ 251 B	Cayman-islands
Bellicum Pharmaceuticals BLCM	-575 M	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	-362 M	-	-7.31 %	$ 87 M	USA
CureVac N.V. CVAC	-1.06 B	-	-	$ 867 M	Germany
Aeterna Zentaris AEZS	-335 M	-	5.93 %	$ 314 M	Canada
Bellerophon Therapeutics BLPH	-252 M	-	-74.18 %	$ 955 K	USA
BioLineRx Ltd. BLRX	-278 M	$ 2.86	1.78 %	$ 908 M	Israel
BioMarin Pharmaceutical BMRN	154 M	$ 60.15	-0.46 %	$ 11.5 B	USA
Equillium EQ	-186 M	$ 1.7	-3.14 %	$ 59 M	USA
Cabaletta Bio CABA	-233 M	$ 3.3	-3.89 %	$ 3.85 M	USA
AIkido Pharma AIKI	-223 M	-	1.93 %	$ 17.4 M	USA
Agenus AGEN	-1.96 B	$ 3.02	-5.63 %	$ 1.08 M	USA
Ayala Pharmaceuticals AYLA	-149 M	-	-	$ 7.46 M	Israel
Capricor Therapeutics CAPR	-159 M	$ 25.16	-1.33 %	$ 674 M	USA
Agios Pharmaceuticals AGIO	-562 M	$ 27.77	-1.49 %	$ 1.61 B	USA